E 06

Drug Profile

E 06

Alternative Names: E-06; S2G6T

Latest Information Update: 18 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Sol-Gel Technologies
  • Class Antifungals; Steroids
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Tinea pedis

Most Recent Events

  • 01 Sep 2016 Phase-II clinical trials in Tinea pedis in USA (Topical) (NCT02842021)
  • 19 Jul 2016 Sol-Gel Technologies plans a phase II trial for Tinea pedis (In adolescents, In adults) in USA (Topical) (NCT02842021)
  • 16 Feb 2016 Preclinical trials in Tinea pedis in USA (Topical) prior to February 2016 (Sol-Gel Technologies' pipeline, February 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top